Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer – Nasdaq
|
Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR–T) Program in Breast Cancer
Nasdaq We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T," stated Steven Quay, MD, PhD, Atossa CEO. "We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T–cell … |
